<DOC>
	<DOCNO>NCT02340962</DOCNO>
	<brief_summary>A Phase 2 , Multicenter , Randomized , Open-label , Dose-ranging Study Evaluate Efficacy Safety TG-2349 Combination Peg-interferon Ribavirin Treatment Naïve East Asian Subjects Chronic Hepatitis C Virus Genotype 1b Infection .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety TG-2349 Combination With Peg-interferon Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1b Infection</brief_title>
	<detailed_description>It multicenter , randomize , open-label study evaluate safety , tolerability , antiviral efficacy two different dos TG-2349 combine Peg-interferon ( IFN ) Ribavirin ( RBV ) HCV-GT1b treatment naïve East Asian subject . The treatment duration TG-2349+IFN+RBV 12 week , without additional 12-week treatment IFN+RBV , depend HCV RNA level On-Treatment Week 4 . Approximately 24 subject randomize ( 1:1 ) one follow 2 treatment group : - Group I ( n=12 ) : 200 mg TG-2349 ( 2 capsule ) + IFN + RBV - Group II ( n=12 ) : 400 mg TG-2349 ( 4 capsule ) + IFN + RBV Randomization stratify IL28B genotype `` CC '' `` non-CC '' . Subjects HCV RNA &lt; LLOQ ( low limit quantification ) , TD ( target detect ) TND ( target detect ) Week 4 receive 12 week TG-2349+IFN+RBV treatment . Subjects HCV RNA ≥ LLOQ &lt; 100 IU/mL Week 4 receive 12 week TG-2349+IFN+RBV treatment follow additional 12 week IFN+RBV treatment . However , subject HCV RNA ≥ 100 IU/mL Week 4 discontinue study treatment complete Early-Termination ( ET ) visit . The study terminate 3 first 12 subject enrol across Groups I II , ≥ 25 % subject thereafter , fail respond treatment ( i.e. , confirm on-treatment virologic failure post-treatment relapse ) . Patients , except achieve SVR12 , offer standard care Peg-interferon Ribavirin duration 24 , 48 , 72 week base Taiwan 's regulatory guideline principal investigator 's judgment .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Willing able provide write informed consent . 2 . East Asian subject , male female , age 18 ( legal adult age ) 70 year , inclusive , Baseline/Day 1 . 3 . Body mass index ( BMI ) range 18.0 35.0 kg/m2 ( inclusive ) body weight ≥ 40 kg . 4 . Presence chronic hepatitis C ( CHC ) document : ( 1 ) A positive antiHCV antibody test positive HCV RNA positive HCV genotyping test least 6 month prior Baseline/Day 1 visit ( 2 ) A liver biopsy FibroTest perform prior Baseline/Day 1 visit evidence chronic HCV infection , presence fibrosis and/or inflammation . 5 . Positive antiHCV antibody Screening . 6 . Presence HCV RNA level ≥ 1 x 10000 IU/mL Screening determine Central Laboratory . 7 . Presence genotype 1b HCVinfection Screening determine Central Laboratory . Any nondefinitive result exclude subject study participation . 8 . HCV treatment naïve define prior therapy interferon ( IFN ) , ribavirin ( RBV ) , approve investigational HCVspecific agent . 9 . Absence cirrhosis Cirrhosis define one following : 1 . Liver biopsy show cirrhosis ( e.g. , Metavir score = 4 Ishak score ≥ 5 ) . 2 . FibroScan show cirrhosis result &gt; 12.5 kPa . 3 . FibroTest fibrosis score &gt; 0.58 APRI ( AST : platelet ratio index ) &gt; 2 Screening . If definitive diagnosis cirrhosis criterion , liver biopsy require ; liver biopsy result supersede noninvasive test result consider definitive . 10 . Screening ECG without clinically significant abnormality . 11 . Subjects must follow laboratory parameter Screening : 1 . ALT ≤ 10 × upper limit normal ( ULN ) 2 . AST ≤ 10 × ULN 3 . Total bilirubin ≤ 1.5 × ULN except history Gilbert 's syndrome . If Gilbert 's syndrome propose etiology , total bilirubin must ≤ 2 × ULN . 4 . Absolute neutrophil count ( ANC ) ≥ 1,500 cells/mm3 5 . Platelet count ≥ 90,000 cells/mm3 6 . HbA1c ≤ 8.5 % 7 . Thyroid stimulate hormone ( TSH ) free T4 ≤ ULN 8 . Creatinine clearance ( CLcr ) ≥ 60 mL /min , calculate CockcroftGault equation 9 . Serum creatinine ≤ 1.5 × ULN 10 . Hemoglobin ≥ 11 g/dL female subject ; ≥ 12 g/dL male subject 11 . Albumin ≥ 3.5 g/dL 12 . INR ( International Normalized Ratio Prothrombin Time ) ≤ 1.5 x ULN unless subject stable anticoagulant regimen affect INR 13 . Antinuclear antibody ( ANA ) ≤ 1:320 . 12 . Subject must generally good health , exception chronic HCV infection , determine Investigator . 13 . Subject must able comply dose instruction study drug administration able complete study schedule assessment , include require PostTreatment visit . 14 . A female subject eligible enter study confirm : ( 1 ) Not pregnant nursing . ( 2 ) Of nonchildbearing potential ( i.e. , woman hysterectomy , ovary remove medically document ovarian failure , postmenopausal woman &gt; 50 year age cessation ( ≥12 month ) previously occur menses ) , ( 3 ) Of childbearing potential ( i.e. , woman hysterectomy , ovary remove , medically document ovarian failure ) . Women ≤ 50 year age amenorrhea consider childbearing potential . These woman must negative serum pregnancy test Screening negative urine pregnancy test Baseline/Day 1 visit prior randomization . They must also agree one follow Screening 6 month last dose study drug ( ) : Complete abstinence intercourse . Periodic abstinence intercourse ( e.g. , calendar , ovulation , symptothermal , postovulation method ) permit . Or Consistent correct use 1 follow method birth control list , addition male partner correctly use condom , Screening 6 month last dose study drug ( ) : 1. intrauterine device ( IUD ) failure rate &lt; 1 % per year 2. female barrier method : cervical cap diaphragm spermicidal agent 3. tubal sterilization 4. vasectomy male partner 5. hormonecontaining contraceptive : i. implant levonorgestrel ii . injectable progesterone iii . oral contraceptive ( either combine progesterone ) iv . contraceptive vaginal ring v. transdermal contraceptive patch . 15 . Male subject must agree consistently correctly use condom , female partner agree use 1 method birth control list , Screening 6 month last dose study drug ( ) . 16 . Male subject must agree refrain sperm donation Screening least 6 month last dose study drug ( ) . 1 . Presence cirrhosis . 2 . Positive serological test IgM antiHAV ( hepatitis A virus ) antibody HBsAg Screening . 3 . Positive ELISA test HIV1 HIV2 Screening . 4 . Chronic liver disease nonHCV etiology ( e.g. , hemochromatosis , Wilson disease , alfa1 antitrypsin deficiency , cholangitis ) . 5 . Donation loss 400 mL blood within 2 month prior Baseline/Day 1 . 6 . Clinicallyrelevant drug abuse within 12 month Screening . A positive drug screen exclude subject unless explain prescribed medication ; diagnosis prescription must approve Investigator . 7 . Alcohol misuse define AUDIT score ≥ 8 . 8 . Contraindications RBV IFN therapy , include hemoglobinopathy ( e.g. , thalassemia major sicklecell anemia ) , autoimmune thyroiditis autoimmune disorder include autoimmune hepatitis . 9 . Pregnant nursing female male pregnant female partner . 10 . Use prohibit medication within 30 day Baseline/Day 1 visit : ( 1 ) Hematologic stimulate agent ( e.g. , erythropoiesisstimulating agent [ ESAs ] , granulocyte colony stimulate factor [ GCSF ] , thrombopoietin [ TPO ] mimetics ) ( 2 ) Chronic use systemic immunosuppressant include , limited , corticosteroid ( prednisone equivalent &gt; 10 mg/day &gt; 2 week ) , azathioprine , monoclonal antibody ( eg , infliximab ) ( 3 ) Investigational agent device indication ( 4 ) Drugs disallow per prescribe information RBV IFN ( 5 ) Any prohibited medication list Table 62 . 11 . Known hypersensitivity RBV , IFN , TG2349 , sulfa drug , formulation excipients . 12 . Current prior history follow : 1 . Clinicallysignificant illness ( HCV ) major medical disorder may interfere subject treatment , assessment compliance protocol ; subject currently evaluation potentially clinicallysignificant illness ( HCV ) also exclude . 2 . Gastrointestinal disorder post operative condition could interfere absorption study drug . 3 . Difficulty blood collection and/or poor venous access purpose phlebotomy . 4 . Clinical hepatic decompensation ( i.e. , ascites , encephalopathy variceal hemorrhage ) . 5 . Central nervous system ( CNS ) trauma , seizure disorder , stroke transient ischemic attack . 6 . Solid organ transplantation . 7 . Significant cardiac disease ( include limit myocardial infarction base ECG and/or clinical history ) . 8 . Significant pulmonary disease porphyria . 9 . Clinically significant retinal disease 10 . Psychiatric hospitalization , suicide attempt , and/or period disability result psychiatric illness within last 5 year . Subjects psychiatric illness ( without prior mention condition ) wellcontrolled stable treatment regimen least 12 month prior Baseline/Day 1 require medication last 12 month may include . 11 . Malignancy within 5 year prior Screening , exception specific cancer entirely cure surgical resection ( basal cell skin cancer , etc ) . Subjects evaluation possible malignancy eligible . 12 . Significant drug allergy ( anaphylaxis hepatotoxicity ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>